COVID-19 Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

COVID-19 Vaccine Market: By Vaccine Type (Inactivated Virus, Protein Subunit, Non-replicating Viral Vector, Repurposed Vaccines, RNA Vaccine, DNA Vaccine, Genetic Vaccine), By Technology (Vector-based, Nucleic acid-based, Protein-based, Whole Virus) and Geograpy

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

COVID-19 vaccine market size is valued at USD billion in 2021 and is expected to reach a value of USD billion by 2028, expected to grow at a significant CAGR from 2022 to 2028. The global market provides a detailed overview and which can be segmented by vaccine type and technology. The COVID-19 vaccine market has been segmented by vaccine type into Inactivated Virus, Protein Subunit, Non-replicating Viral Vector, Repurposed Vaccines, RNA Vaccine, DNA Vaccine, and Genetic Vaccine. The RNA Vaccine segment is likely the largest and fastest-growing in terms of vaccine types. Based on technology, the COVID-19 vaccine is segmented into Vector-based, Nucleic acid-based, Protein-based, and Whole Viruses. According to precision business insights, the Vector-based segment is predicted to register the fastest growth rate during the forecast period.

Key Development:

In October 2021, Pfizer received the US FDA Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.

In August 2021, Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full US FDA approval for individuals 16 years and older.

COVID-19 Vaccine Market

MARKET SUMMARY
-
x%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– x%
  • Largest Market– North America
  • Fastest Growing Market–  Asia-Pacific

COVID-19 Vaccine Market

  • The COVID-19 vaccine market report gives comprehensive outlook on hydrogen fluoride across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The report on COVID-19 vaccine market gives historical, current, and future market sizes (US$ Mn) based on vaccine type, technology and geography.
Key Players
  • AstraZeneca
  • GlaxoSmithKline
  • Moderna
  • Gamaleya
  • Bharat Biotech
COVID-19 Vaccine Market Drivers

With greater healthcare awareness, the focus on immunization has shifted significantly, and various government agencies are working to achieve this goal. For example, Immunise Australia is an Australian government program that helps people buy immunizations.


Asia-Pacific Got Significant Share

COVID-19 Vaccine Market

The Asia Pacific market is expected to witness the largest market share during the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The COVID-19 vaccine market report provides granular level information about the market size, regional market share, historic market (2017-2021), and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
COVID-19 Vaccine Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The COVID-19 vaccine market is projected to expand at a CAGR of x% during the forecast period.

The major global COVID-19 vaccine market players are ​​​ AstraZeneca, GlaxoSmithKline, Moderna, Gamaleya, Bharat Biotech, Pfizer, Johnson & Johnson, BioNTech, CureVac, Serum Institute of India, Novavax, Sinovac, and Sinopharm.

Asia Pacific is the fastest-growing region for COVID-19 vaccine arket


Report

Table Of Content

1. Executive Summary
2. Global COVID-19 Vaccine Market Introduction
2.1. Global COVID-19 Vaccine Market – Taxonomy
2.2. Global COVID-19 Vaccine Market –Definitions
2.2.1. By Vaccine Type
2.2.2. By Technology
2.2.3. By Region
3. Global COVID-19 Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global COVID-19 Vaccine Market Dynamic Factors – Impact Analysis
3.6. Global COVID-19 Vaccine Market – Competition Landscape
4. Global COVID-19 Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global COVID-19 Vaccine Market, By Vaccine Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Inactivated Virus
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Protein Subunit
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Non-replicating Viral Vector
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Repurposed Vaccines
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. RNA Vaccine
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. DNA Vaccine
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Genetic Vaccine
5.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6. Global COVID-19 Vaccine Market, By Technology, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Vector-based
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Nucleic acid-based
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Protein-based
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Whole Virus
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global COVID-19 Vaccine Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global COVID-19 Vaccine Market – Opportunity Analysis Index, By Vaccine Type, Technology, and Region, 2022 – 2028
8. North America COVID-19 Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Inactivated Virus
8.1.2. Protein Subunit
8.1.3. Non-replicating Viral Vector
8.1.4. Repurposed Vaccines
8.1.5. RNA Vaccine
8.1.6. DNA Vaccine
8.1.7. Genetic Vaccine
8.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Vector-based
8.2.2. Nucleic acid-based
8.2.3. Protein-based
8.2.4. Whole Virus
8.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America COVID-19 Vaccine Market – Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2022 – 2028
8.5. North America COVID-19 Vaccine Market Dynamics – Trends
9. Europe COVID-19 Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Inactivated Virus
9.1.2. Protein Subunit
9.1.3. Non-replicating Viral Vector
9.1.4. Repurposed Vaccines
9.1.5. RNA Vaccine
9.1.6. DNA Vaccine
9.1.7. Genetic Vaccine
9.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Vector-based
9.2.2. Nucleic acid-based
9.2.3. Protein-based
9.2.4. Whole Virus
9.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe COVID-19 Vaccine Market – Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2022 – 2028
9.5. Europe COVID-19 Vaccine Market Dynamics – Trends
10. Asia-Pacific COVID-19 Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Inactivated Virus
10.1.2. Protein Subunit
10.1.3. Non-replicating Viral Vector
10.1.4. Repurposed Vaccines
10.1.5. RNA Vaccine
10.1.6. DNA Vaccine
10.1.7. Genetic Vaccine
10.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Vector-based
10.2.2. Nucleic acid-based
10.2.3. Protein-based
10.2.4. Whole Virus
10.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific COVID-19 Vaccine Market – Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2022 – 2028
10.5. Asia-Pacific COVID-19 Vaccine Market Dynamics – Trends
11. Latin America COVID-19 Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Inactivated Virus
11.1.2. Protein Subunit
11.1.3. Non-replicating Viral Vector
11.1.4. Repurposed Vaccines
11.1.5. RNA Vaccine
11.1.6. DNA Vaccine
11.1.7. Genetic Vaccine
11.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Vector-based
11.2.2. Nucleic acid-based
11.2.3. Protein-based
11.2.4. Whole Virus
11.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America COVID-19 Vaccine Market – Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2022 – 2028
11.5. Latin America COVID-19 Vaccine Market Dynamics – Trends
12. Middle East and Africa COVID-19 Vaccine Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. Vaccine Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Inactivated Virus
12.1.2. Protein Subunit
12.1.3. Non-replicating Viral Vector
12.1.4. Repurposed Vaccines
12.1.5. RNA Vaccine
12.1.6. DNA Vaccine
12.1.7. Genetic Vaccine
12.2. Technology Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Vector-based
12.2.2. Nucleic acid-based
12.2.3. Protein-based
12.2.4. Whole Virus
12.3. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA COVID-19 Vaccine Market – Opportunity Analysis Index, By Vaccine Type, Technology, and Country, 2022 – 2028
12.5. MEA COVID-19 Vaccine Market Dynamics – Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Vaccine Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. AstraZeneca
13.2.2. GlaxoSmithKline
13.2.3. Moderna
13.2.4. Gamaleya
13.2.5. Bharat Biotech
13.2.6. Pfizer
13.2.7. Johnson & Johnson
13.2.8. BioNTech
13.2.9. CureVac
13.2.10. Serum Institute of India
13.2.11. Novavax
13.2.12. Sinovac
13.2.13. Sinopharm
14. Research Methodology
15. Key Assumptions and Acronyms

Report

Company Profile

  • AstraZeneca
  • GlaxoSmithKline
  • Moderna
  • Gamaleya
  • Bharat Biotech
  • Pfizer
  • Johnson & Johnson
  • BioNTech
  • CureVac
  • Serum Institute of India
  • Novavax
  • Sinovac
  • Sinopharm

Description

COVID-19 vaccine market size is valued at USD billion in 2021 and is expected to reach a value of USD billion by 2028, expected to grow at a significant CAGR from 2022 to 2028. The global market provides a detailed overview and which can be segmented by vaccine type and technology. The COVID-19 vaccine market has been segmented by vaccine type into Inactivated Virus, Protein Subunit, Non-replicating Viral Vector, Repurposed Vaccines, RNA Vaccine, DNA Vaccine, and Genetic Vaccine. The RNA Vaccine segment is likely the largest and fastest-growing in terms of vaccine types. Based on technology, the COVID-19 vaccine is segmented into Vector-based, Nucleic acid-based, Protein-based, and Whole Viruses. According to precision business insights, the Vector-based segment is predicted to register the fastest growth rate during the forecast period.

Key Development:

In October 2021, Pfizer received the US FDA Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age.

In August 2021, Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full US FDA approval for individuals 16 years and older.

Reviews

There are no reviews yet.

Be the first to review “COVID-19 Vaccine Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX